Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
- 31 December 2008
- journal article
- Published by Elsevier BV in Molecular Immunology
- Vol. 46 (2), 225-232
- https://doi.org/10.1016/j.molimm.2008.08.276
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnoverMolecular Immunology, 2008
- Complement evasion by human pathogensNature Reviews Microbiology, 2008
- Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicityToxicology, 2005
- Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera: A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levelsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Mannose‐Binding Lectin Accelerates Complement Activation and Increases Serum Killing ofNeisseria meningitidisSerogroup CThe Journal of Infectious Diseases, 2001
- ComplementThe New England Journal of Medicine, 2001
- ComplementThe New England Journal of Medicine, 2001
- Complement Activation in Rats by Liposomes and Liposome-Encapsulated Hemoglobin: Evidence for Anti-lipid Antibodies and Alternative Pathway ActivationBiochemical and Biophysical Research Communications, 1994
- Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol®The American Journal of Cardiology, 1990
- Pulmonary complications after Fluosol administration to patients with life-threatening blood lossCritical Care Medicine, 1985